4 Madan RA, Arlen PM, Mohebtash M, et al. Prostvac- VF: a vector- based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001–11. 5 Gulley J, Chen AP , Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV- PSA) in patients with metastatic androgen- independent prostate cancer. Prostate 2002;53:109–17. 6 Gulley JL, Madan RA, Tsang KY , et al. Immune impact induced by PROSTVAC (PSA- TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2014;2:133–41. 7 Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral- based PSA- targeted immunotherapy in metastatic castration- resistant prostate cancer. J Clin Oncol 2010;28:1099–105. 8 Gulley JL, Borre M, Vogelzang NJ, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration- resistant prostate cancer. J Clin Oncol 2019;37:1051–61.